- Home
- NYT vs VRNA Comparison
NYT vs VRNA Comparison
Compare NYT & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYT
- VRNA
- Stock Information
- Founded
- NYT 1851
- VRNA 2005
- Country
- NYT United States
- VRNA United Kingdom
- Employees
- NYT N/A
- VRNA N/A
- Industry
- NYT Newspapers/Magazines
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- NYT Consumer Discretionary
- VRNA Health Care
- Exchange
- NYT Nasdaq
- VRNA Nasdaq
- Market Cap
- NYT 9.3B
- VRNA 8.3B
- IPO Year
- NYT N/A
- VRNA 2017
- Fundamental
- Price
- NYT $58.50
- VRNA $106.26
- Analyst Decision
- NYT Buy
- VRNA Buy
- Analyst Count
- NYT 6
- VRNA 11
- Target Price
- NYT $60.33
- VRNA $114.10
- AVG Volume (30 Days)
- NYT 1.3M
- VRNA 1.4M
- Earning Date
- NYT 11-03-2025
- VRNA 11-03-2025
- Dividend Yield
- NYT 1.24%
- VRNA N/A
- EPS Growth
- NYT 19.25
- VRNA N/A
- EPS
- NYT 1.93
- VRNA N/A
- Revenue
- NYT $2,661,490,000.00
- VRNA $221,673,000.00
- Revenue This Year
- NYT $9.93
- VRNA $896.59
- Revenue Next Year
- NYT $6.51
- VRNA $77.56
- P/E Ratio
- NYT $30.20
- VRNA N/A
- Revenue Growth
- NYT 7.88
- VRNA N/A
- 52 Week Low
- NYT $44.83
- VRNA $27.54
- 52 Week High
- NYT $62.24
- VRNA $106.45
- Technical
- Relative Strength Index (RSI)
- NYT 50.72
- VRNA 67.69
- Support Level
- NYT $57.16
- VRNA $106.18
- Resistance Level
- NYT $59.05
- VRNA $106.42
- Average True Range (ATR)
- NYT 0.96
- VRNA 0.19
- MACD
- NYT -0.21
- VRNA -0.17
- Stochastic Oscillator
- NYT 47.08
- VRNA 74.32
About NYT New York Times Company (The)
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company has two segments: New York Times Group and The Athletic. The company generates the majority of its revenue from the NYTG segment. The NYTG and The Athletic segments derive revenue from subscriptions, Advertising, and others, where the majority source of revenue for both segments is subscription.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.